Lilly’s Zepbound vs. Novo’s Wegovy: The Weight-Loss Drug Race Has Officially Started

Lilly’s Zepbound vs. Novo’s Wegovy: The Weight-Loss Drug Race Has Officially Started

Source: 
Motley Fool
snippet: 

The other shoe finally dropped this week in the lucrative weight-loss market, with the FDA’s much-anticipated approval of Eli Lilly’s obesity drug Zepbound (tirzepatide). The regulatory decision on Wednesday cleared tirzepatide, which was previously approved for type 2 diabetes as Mounjaro, under the brand name Zepbound to treat obesity and overweight patients who also have weight-related medical problems such as hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.